Department für Radiologische Diagnostik und Therapie

Klinik für Strahlenheilkunde

Robert Koch Str. 3
79106 Freiburg
Tel: 0049-761-270-9461 Fax: 0049-761-270-9472
Email anca.grosu@uniklinik-freiburg.de



Wissenschaftliche Mitarbeiterinnen und Mitarbeiter

  • Prof. Dr. Dr. h.c. Hermann Frommhold, Ärztlicher Direktor
  • PD Dr. med. Michael Henke, Ltd. Oberarzt
  • Dr. med. Michaela Fritz
  • PD Dr. med. Johannes Lutterbach
  • PD Dr. med. Frank Pajonk
  • Dr. med. Annette Barke
  • Dr. med. Susanne Bartelt
  • Dr. med. Marianne Schmucker, Geschäftsführende Oberärztin
  • Dr. med. Christian Weißenberger
  • Dr. med. Karl Henne, OA
  • Dr. med. Stephan Hennings
  • Dr. medic/IM Temeschburg Carmen Martini, OÄ
  • Dr. med. Birgit Opferkuch
  • Dr. med. Jutta Scholber, OÄ
  • Dr. rer.nat. Siegfried Stange
  • Dr. med. Inge Uhlig, OÄ
  • Dr. med. Christina Hanser
  • Dr. med. Eva Lewandowski
  • Dr. med. Tanja Schimek-Jasch
  • Dr. med. Petra Stegmaier
  • Dr. /VAK Moskau Natascha Volegova-Neher
  • Dr. rer.nat. Gregor Bruggmoser, Leitender Physiker
  • Dr. rer. nat. Norbert Hodapp
  • Dipl. Phys. Sophie Küchler
  • Dr. rer. nat. Fred Röhner
  • Dr. med. Felix Heinemann, Leiter Klinische und Administrative Informatik
Einträge in der Rubrik "Who is Who"

Finanzierung

  • Lutterbach J: Ministerium für Wissenschaft, Forschung und Kunst Baden-Württemberg (AZ 7851)

Wissenschaftliche Projekte und Forschungsvorhaben


  • Aufklärung in der Onkologie - Systematische Evaluation von Patientensicht und Patientenbedürfnissen
  • Der Einsatz von Proteaseinhibitoren in der Strahlentherapie maligner Tumoren
  • Molekulare Mechanismen der Modulation der Strahlenantwort maligner Tumore durch Erythropoietin.
  • Oncocase - Verbundpilotprojekt internetbasiertes multimediales Lehr-/Lern- und Evaluationsprogramm in Verbindung mit konventionellem Präsenzstudium in Kleingruppen

Wissenschaftliche Publikationen

Originalarbeiten in wissenschaftlichen Fachzeitschriften:
  • Arab A, Grumann T, Guttenberger R, Bode C, Hehrlein C: Reoxygenation of hypoxic coronary smooth muscle cells amplifies growth-retarding effects of ionizing irradiation. Circulation, 2004; 109 (8): 1036-1040.
  • Bartelt S, Momm F, Weissenberger Ch, Lutterbach J: Patients with brain metastases from gastrointestinal tract cancer treated with whole brain radiation therapy: Prognostic factors and survival World J Gastroentero, 2004; 12 (22): 3345-3348.
  • Brink I, Schumacher T, Mix M, Ruhland S, Stoelben E, Digel W, Henke M, Ghanems N, Moser E, Nitzsche EU: Impact of [(18)F] FDG-PET on the primary staging of small-cell lung cancer Eur J Nucl Med Mol I, 2004. (in Druck)
  • Brunner T, Johr M: Anesthetic management of a child with xeroderma pigmentosum. Paediatr Anaesth, 2004; 14 (8): 697-698. : http://dx.doi.org/10.1111/j.1460-9592.2004.01367.x
  • Brunner T, Martin SJ: c-Myc: where death and division collide. Cell Cycle, 2004; 3 (4): 456-459.
  • Brunner TB, Hahn SM, McKenna WG, Bernhard EJ: Radiation sensitization by inhibition of activated Ras. Strahlenther Onkol, 2004; 180 (11): 731-740. : http://dx.doi.org/10.1007/s00066-004-9198-8
  • Brunner TB, Schwab D, Meyer T, Sauer R: Chemoradiation may prolong survival of patients with non-bulky unresectable extrahepatic biliary carcinoma. A retrospective analysis. Strahlenther Onkol, 2004; 180 (12): 751-757. : http://dx.doi.org/10.1007/s00066-004-1315-1
  • Cima I, Corazza N, Dick B, Fuhrer A, Herren S, Jakob S, Ayuni E, Mueller C, Brunner T: Intestinal epithelial cells synthesize glucocorticoids and regulate T cell activation. J Exp Med, 2004; 200 (12): 1635-1646. : http://dx.doi.org/10.1084/jem.20031958
  • Corazza N, Brumatti G, Jakob S, Villunger A, Brunner T: TRAIL and thymocyte apoptosis: not so deadly? Cell Death Differ, 2004; 11 Suppl 2: S213-S215. : http://dx.doi.org/10.1038/sj.cdd.4401525
  • Corazza N, Brumatti G, Schaer C, Cima I, Wasem C, Brunner T: TRAIL and immunity: more than a license to kill tumor cells. Cell Death Differ, 2004; 11 Suppl 2: S122-S125. : http://dx.doi.org/10.1038/sj.cdd.4401542
  • Corazza N, Brunner T, Buri C, Rihs S, Imboden MA, Seibold I, Mueller C: Transmembrane tumor necrosis factor is a potent inducer of colitis even in the absence of its secreted form. Gastroenterology, 2004; 127 (3): 816-825.
  • Engler OB, Schwendener RA, Dai WJ, Wolk B, Pichler W, Moradpour D, Brunner T, Cerny A: A liposomal peptide vaccine inducing CD8+ T cells in HLA-A2.1 transgenic mice, which recognise human cells encoding hepatitis C virus (HCV) proteins. Vaccine, 2004; 23 (1): 58-68. : http://dx.doi.org/10.1016/j.vaccine.2004.05.009
  • Fritzsche K, Liptai C, Henke M: Psychosocial distress and need for psychotherapeutic treatment in cancer patients undergoing radiotherapy Radiother Oncol, 2004; 72: 183-189.
  • Henke M: Erythropoietin and Curative Cancer Treatment. The American Journal of Oncology Review, 2004; 3 (4): 190-192.
  • Henke M, Laszig R, Frommhold H: Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet, 2004; 363 (9402): 81-82.
  • Henke M, Pajonk F: Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet, 2004; 363 (9413): 993-993.
  • Henke M, Sindlinger F, Ikenberg H, Gerds T, Schumacher M: Blood hemoglobin level and treatment outcome of early breast cancer. Strahlenther Onkol, 2004; 180 (1): 45-51.
  • Kortmann RD, Jeremic B, Weller M, Lutterbach J, Paulsen F, Bamberg M: Immediate postoperative radiotherapy or "watch and wait" in the management of adult low-grade glioma? Strahlenther Onkol, 2004; 180 (7): 408-418.
  • Lutterbach J, Weissenberger C, Hitzer K, Helmes A: [On past practices and future directions of informed consent in (radiation) oncology] Strahlenther Onkol, 2004; 180 (8): 469-477.
  • Martin NE, Brunner TB, Kiel KD, DeLaney TF, Regine WF, Mohiuddin M, Rosato EF, Haller DG, Stevenson JP, Smith D, Pramanik B, Tepper J, Tanaka WK, Morrison B, Deutsch P, Gupta AK, Muschel RJ, McKenna WG, Bernhard EJ, Hahn SM: A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer. Clin Cancer Res, 2004; 10 (16): 5447-5454. : http://dx.doi.org/10.1158/1078-0432.CCR-04-0248
  • McBride WH, Chiang CS, Olson J, Wang CC, Hong JH, Pajonk F, Dougherty G, Iwamoto K, Pervan M, Liao YP: A Sense of Danger from Radiation Radiat Res, 2004; 162 (1): 1-19.
  • Momm F, Becker G, Bartelt S, Guttenberger R: The old, fragile tumour patient: radiotherapy as a most effective and most feasible palliative treatment modality. J Pain Symptom Manag, 2004; 27 (1): 3-4.
  • Momm F, Becker G, Ewald H, Baumgartner J, Adamietz IA, Frommhold H: Strahlentherapeutische Beteiligung an interdisziplinären palliativmedizinischen Einrichtungen - Herausforderung und Chance. Strahlenther Onkol, 2004; 180 (2): 73-77.
  • Pajonk F, Scholber UJ, Fiebich B: Inhibition of Proteasome Function Contributes to Effects and Side-Effects of Hypericin Cancer Chemoth Pharm, 2004. (in Druck)
  • Pajonk F, Weil A, Sommer A, Suwinksi R, Henke M: The Erythropoietin-ReceptorPathway Modulates Survival of Cancer Cells Oncogene, 2004. (in Druck)
  • Schipper J, Henke M: Erythropoietin in patients with head and neck carcinomas? Laryngo Rhino Otol, 2004; 83 (5): 292-297.
  • Schreiber FS, Deramaudt TB, Brunner TB, Boretti MI, Gooch KJ, Stoffers DA, Bernhard EJ, Rustgi AK: Successful growth and characterization of mouse pancreatic ductal cells: functional properties of the Ki-RAS(G12V) oncogene. Gastroenterology, 2004; 127 (1): 250-260.
  • Schulze-Bonhage A, , Lutterbach J, , Ostertag C: Diagnostik und Therapie bei gelastischen Epilepsien Z Epileptol, 2004; 17: 279-286.
  • Torgler R, Jakob S, Ontsouka E, Nachbur U, Mueller C, Green DR, Brunner T: Regulation of activation-induced Fas (CD95/Apo-1) ligand expression in T cells by the cyclin B1/Cdk1 complex. J Biol Chem, 2004; 279 (36): 37334-37342. : http://dx.doi.org/10.1074/jbc.M406913200
  • Trotti A, Garden A, Warde P, Symonds P, Langer C, Redman R, Pajak TF, Fleming TR, Henke M, Bourhis J, Rosenthal DI, Junor E, Cmelak A, Sheehan F, Pulliam J, Devitt-Risse P, Fuchs H, Chambers M, O'Sullivan B, Ang KK: A multinational, randomized phase III trial of iseganan hcl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck-malignancy. Int J Radiat Oncol, 2004; 58 (3): 674-681.
  • Weissenberger C, Jonassen S, Beranek-Chiu J, Neumann M, Muller D, Bartelt S, Schulz S, Monting JS, Henne K, Gitsch G, Witucki G: Breast cancer: patient information needs reflected in English and German web sites. Brit J Cancer, 2004; 91 (8): 1482-1487.
  • Wiener Z, Ontsouka EC, Jakob S, Torgler R, Falus A, Mueller C, Brunner T: Synergistic induction of the Fas (CD95) ligand promoter by Max and NFkappaB in human non-small lung cancer cells. Exp Cell Res, 2004; 299 (1): 227-235. : http://dx.doi.org/10.1016/j.yexcr.2004.05.031
Buchbeiträge:
  • Pajonk F, McBride WH: The Proteasome in Cancer Biology and Therapy. In: Adams Julian (Hrsg.): Proteasome Inhibitors in Cancer Therapy Cancer Drug Discovery and Development HUMANA Press, 2004; 111-121.
  • Weissenberger C, Bartsch HH, Weis J: Das Internet als Informationsquelle - Etablierung methodischer Verfahren zur Qualitätsevaluation. In: Bartsch HH, Weis J (Hrsg.): Tumortherapie und Rehabilation Basel; Freiburg; Paris; London; New York,: Karger Verlag, 2004; 1-17.
Vorträge:
  • Weissenberger C: Internet use and Outcome. 2004 (Deutscher Krebskongress).
  • Weissenberger C: Psychosocial factors and Internet use. 2004 (Deutscher Krebskongress).
  • Weissenberger C: Psychosocial factors of cancer patients and use of the internet as a source of oncological information 2004 (Deutscher Krebskongress Berlin).
Konferenzbeiträge:
  • Weissenberger C, Jonassen S, Beranek-Chiu J, Müller D, Neumann M, Lutterbach J, Witucki G: Psychological factors of cancer patients and use of the internet as a source of oncological information. J Cancer Res Clin Oncol, 2004; 130 Suppl. 1: 186.
  • Weissenberger C, Jonassen S, Beranek-Chiu J, Müller D, Neumann M, Witucki G: The Factor "Internet information" and outcome of cancer - how to design a study to evaluate the impact and preliminary results J Cancer Res Clin Oncol, 2004; 130 Suppl. 1: 196.

Besondere wissenschaftliche Aktivitäten

Preise / Ehrungen:
  • PD Dr. med. Frank Pajonk: Langendorff-Preis, 2004.
  • Prof. Dr. med. Michael Henke: Eleonore-und-Fritz-Hodeige-Preis für innovative klinische Forschung, 2004.
  • Prof. Dr. med. Michael Henke: ARO-Studienpreis für herausragende klinische Forschung, 2004.

Abschlussarbeiten